Skip to main content
. 2022 Jan 29;79(2):104. doi: 10.1007/s00018-021-04056-6

Fig. 2.

Fig. 2

Clinical association of MED12 expression across different grades of glioma and its correlation with patient prognosis: a expression of MED12 across different subtypes of gliomas. Graph from GlioVis showing higher expression of MED12 in astrocytoma and oligodendroglioma as compared to glioblastoma in (i) TCGA_GBMLGG dataset (ii) Rembrandt dataset. (iii) Gravendeel dataset. b Expression of MED12 across low grade gliomas. Graph from GlioVis showing higher expression of MED12 in grade II and grade III tumors as compared to glioblastoma in (i) TCGA_GBMLGG dataset. (ii) Rembrandt dataset. (iii) Gravendeel dataset. c Prognosis of glioblastoma patients in relation to MED12 over-expression (i) Kaplan–Meier curve from GlioVis (CGGA dataset) showing significant correlation of MED12 high expression with poor patient prognosis in glioblastoma. (ii) Kaplan–Meier curve from Prognoscan database displaying significant correlation of MED12 high expression with poor patient prognosis in glioblastoma. (iii) Kaplan–Meier curve from GlioVis (Murat dataset) database displaying significant correlation of MED12 high expression with poor patient prognosis in glioblastoma. (iv, v, vi) Kaplan–Meier curve from GlioVis (TCGA_GBM, Rembrandt and Gravendeel dataset) database displaying no significant correlation of MED12 expression with patient prognosis in glioblastoma. d Prognosis of glioma patients in relation to MED12 over-expression. (i) Kaplan–Meier curve from Prognoscan analysing GSE4412-GPL96 dataset showing high expression of MED12 promotes patient prognosis in glioma. (ii) Kaplan–Meier curve from GlioVis analysing TCGA_GBMLGG dataset showing high expression of MED12 promotes patient prognosis in astrocytoma. (iii) Kaplan–Meier curve from CGGA showing high expression of MED12 promotes patient prognosis in grade II glioma